Therapeutic targeting of TGFβ in combination with immune checkpoint blockade has shown promising results in preclinical models [185,186], and can even promote the transition of the tumor immune phenotype from immune-desert to immune-inflamed [2]. Here, TGFB1 is linked to neoplasm.